AstraZeneca is in serious talks to merge with Bristol Myers Squibb, potentially creating a $300 billion pharma giant — the world’s fourth-largest. While the deal could supercharge AstraZeneca’s U.S. footprint, it also fuels concerns about British firms abandoning London. Regulatory hurdles loom large, especially with antitrust scrutiny and current political priorities on domestic investment. Meanwhile, CEO Pascal Soriot downplays M&A as essential, hinting that internal growth may be enough — adding complexity to the already tangled merger landscape.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
